BC Innovations | Jun 13, 2019
Product Development

Why BioMarin took gene therapy manufacturing into its own hands

As gene therapy companies fight for space at contract manufacturers, BioMarin has leveraged its expertise in biologics to design its own capabilities for manufacturing gene therapies and gain control of the process -- a move...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BC Extra | Aug 13, 2018
Company News

Amicus prices Galafold at $315k per year

Amicus Therapeutics Inc. (NASDAQ:FOLD) said Monday that it will price Galafold migalastat at $315,000 per year and vowed to limit annual price increases of the Fabry disease drug to the rate of inflation. On Friday,...
BC Week In Review | Oct 20, 2017
Company News

Chiesi licenses Protalix's Fabry's disease candidate

Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) ex-U.S. rights to pegunigalsidase alfa (PRX-102), which is in Phase III testing to treat Fabry's disease. Protalix will receive $25 million up front....
BC Extra | Oct 18, 2017
Company News

Chiesi, Protalix in ex-U.S. Fabry's deal

Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX) said it granted Chiesi Farmaceutici S.p.A. (Parma, Italy) ex-U.S. rights to pegunigalsidase alfa ( PRX-102 ), which is in Phase III testing to treat Fabry's disease. Protalix will receive $25...
BioCentury | May 20, 2017
Strategy

Henri: N of 1

Gaucher’s disease had swollen Brian Berman’s spleen to the size of a basketball and physicians at NIH told the three-year-old’s parents that it had to be removed. It was 1984, there was no effective treatment...
BC Week In Review | Jun 13, 2016
Clinical News

Alpha galactosidase: Phase III started

Protalix began the double-blind, international Phase III BALANCE Study to compare 1 mg/kg IV PRX-102 vs. 1 mg/kg IV Fabrazyme agalsidase beta every 2 weeks for 2 years. The trial is enrolling 78 patients with...
BioCentury | Mar 28, 2016
Strategy

Canbridge can-can

Canbridge Life Sciences Ltd .'s deal with Aveo Pharmaceuticals Inc. will see the Chinese biotech developing its first programs outside Asia. But Chairman and CEO James Xue says the company is not deviating from its...
BC Extra | Apr 29, 2015
Clinical News

Sanofi oral Fabry's therapy gets Fast Track

The Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) said FDA granted Fast Track designation for GZ402671 to treat Fabry's disease. Last week, Sanofi began a Phase IIa trial of the glucosylceramide synthase (GCS) inhibitor. GZ402671...
Items per page:
1 - 10 of 368